Valuation: Abpro Holdings, Inc.

Market Cap 1.26M 1.09M 1.02M 932K 1.75M 121M 1.78M 12M 4.69M 60.45M 4.74M 4.64M 201M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 1.34M 1.16M 1.09M 991K 1.86M 128M 1.89M 12.77M 4.99M 64.28M 5.04M 4.93M 214M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
1 day+19.64%
1 week-21.04%
Current month-6.00%
1 month-1.30%
3 months-4.03%
6 months-73.14%
Current year-95.33%
1 week 0.19
Extreme 0.1925
0.24
1 month 0.19
Extreme 0.1925
0.26
Current year 0.09
Extreme 0.0866
5.08
1 year 0.09
Extreme 0.0866
8.49
3 years 0.09
Extreme 0.0866
390
5 years 0.09
Extreme 0.0866
390
10 years 0.09
Extreme 0.0866
390
Date Insider Type Main position Quantity % Market Cap.
7/31/25 Buy

Chief Executive Officer

72,035 0.1386%
7/25/25 Free

Director

60,600 0.1166%
7/25/25 Free

Director

60,600 0.1166%
Change 5-day change 1-year change 3-year change Capi.($)
+19.64%-21.04%-97.53%-99.94% 1.26M
+0.11%-2.73%+1.44%+19.15% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
-1.33%-0.77%+3.21%+26.82% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average +1.37%-0.31%+58.41%+93.46% 26.31B
Weighted average by Cap. -0.66%-0.62%+95.77%+140.66%

Financials

2024 2025
Net sales 183K 158K 149K 135K 254K 17.5M 258K 1.74M 680K 8.76M 687K 672K 29.12M -
Net income -7.23M -6.25M -5.87M -5.34M -10.04M -692M -10.2M -68.77M -26.89M -346M -27.15M -26.56M -1.15B -2.89M -2.5M -2.35M -2.13M -4.01M -277M -4.08M -27.5M -10.75M -138M -10.86M -10.62M -460M
Net Debt 478K 413K 388K 353K 663K 45.71M 674K 4.55M 1.78M 22.89M 1.79M 1.76M 76.06M 80K 69.1K 64.93K 59.05K 111K 7.65M 113K 761K 297K 3.83M 300K 294K 12.73M
Logo Abpro Holdings, Inc.
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
2
Date Price Change Volume
26-08-14 US$0.2141 -2.02% 3,602
26-08-13 US$0.2185 -.--% 12,163
26-08-12 US$0.2185 -1.58% 32,510
26-08-11 US$0.2220 -10.99% 28,867
26-08-10 US$0.2494 -0.24% 6,871

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABPO Stock